GLP1R and neoplasm: In an earlier meta-analysis by Figlioli and colleagues, the authors pooled different kinds of gastrointestinal tract tumors into a whole group, ignoring the different site-specific tumor risk factors, and achieved results that overall GLP-1 receptor agonists would not alter the risk of overall gastrointestinal tract tumors[20].